Vincristine efficacy and safety in treating immune thrombocytopenia: A retrospective study of 35 patients

European Journal of Haematology

Volumn 96, Issue 3, 2016, Pages 269-275

  Stirnemann, Jérôme ^a,b   Kaddouri, Najett ^a   Khellaf, Medhi ^c   Morin, Anne Sophie ^a   Prendki, Virginie ^a,b   Michel, Marc ^c   Mekinian, Arsène ^a,d   Bierling, Philippe ^c   Fenaux, Pierre ^e   Godeau, Bertrand ^c   Fain, Olivier ^a,d  

^a UNIVERSITÉ PARIS 13   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Efficacy; Emergency; Immune thrombocytopenia; Safety; Vincristine

Indexed keywords

CORTICOSTEROID; DAPSONE; HYDROXYCHLOROQUINE; MYCOPHENOLATE MOFETIL; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; ILEUS; INTESTINE OBSTRUCTION; KAPLAN MEIER METHOD; MALE; MEDIAN SURVIVAL TIME; NEUROPATHY; PERIPHERAL NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT FAILURE; VERY ELDERLY; FOLLOW UP; MIDDLE AGED; MORTALITY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84958107880     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12586     Document Type: Article

References (23)

1. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207.
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
3. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51.
4. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359:23-9.
5. Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007;14:535-56.
6. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
7. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
8. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010;150:9-20.
9. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007;110:3526-31.
10. Robertson JH, McCarthy GM. Periwinkle alkaloids and the platelet-count. Lancet 1969;2:353-5.
11. Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med 1974;291:376-80.
12. Manoharan A. Slow infusion of vincristine in the treatment of idiopathic thrombocytopenic purpura. Am J Hematol 1986;21:135-8.
13. Linares M, Cervero A, Sanchez M, Garcia S, Miguel-Sosa A, Miguel-Garcia A, Miguel-Borja JM. Slow infusion of vincristine in the treatment of refractory thrombocytopenic purpura. Acta Haematol 1988;80:173-4.
14. Facon T, Caulier MT, Wattel E, Jouet JP, Bauters F, Fenaux P. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994;86:678-80.
15. Fenaux P, Quiquandon I, Caulier MT, Simon M, Walter MP, Bauters F. Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases. Blut 1990;60:238-41.
16. Burton IE, Roberts BE, Child JA, Montgomery DA, Raper CG. Responses to cinvristine in refractory idiopathic thrombocytopenic purpura. Br Med J 1976;2:918.
17. Cervantes F, Montserrat E, Rozman C, Diumenjo C, Feliu E, Granena A. Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. Postgrad Med J 1980;56:711-4.
18. Ahn YS, Harrington WJ, Mylvaganam R, Allen LM, Pall LM. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med 1984;100:192-6.
19. Sikorska A, Slomkowski M, Marlanka K, Konopka L, Gorski T. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. Clin Lab Haematol 2004;26:407-11.
20. Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol 2007;29:347-51.
21. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
22. Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol Suppl 2009;71:8-12.
23. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.